TheraRadar
← Back
Data updated: Jul 17, 2026

NORTHSTAR HLTHCARE

Generics

NORTHSTAR HLTHCARE is a generic drug manufacturer focused on Neurology, Cardiovascular.

2007
Since
9
Drugs
-
Trials
0
New Drugs (2yr)

NORTHSTAR HLTHCARE's Key Drugs

NORTHSTAR HLTHCARE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

NORTHSTAR HLTHCARE's Recent FDA Approvals

New NDA/BLA approvals for NORTHSTAR HLTHCARE over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

NORTHSTAR HLTHCARE's Therapeutic Areas

NORTHSTAR HLTHCARE's approved drugs and pipeline span 2 therapeutic areas, led by Neurology and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 50%
2 drugs
Cardiovascular 50%
2 drugs

NORTHSTAR HLTHCARE's Top Competitors

NORTHSTAR HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

NORTHSTAR HLTHCARE Pipeline Snapshot

Active clinical trials for NORTHSTAR HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling